D
David Bloxham
Researcher at Cambridge University Hospitals NHS Foundation Trust
Publications - 26
Citations - 2098
David Bloxham is an academic researcher from Cambridge University Hospitals NHS Foundation Trust. The author has contributed to research in topics: Myeloid & Karyotype. The author has an hindex of 12, co-authored 25 publications receiving 1881 citations. Previous affiliations of David Bloxham include University of Cambridge.
Papers
More filters
Journal ArticleDOI
Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
Jyoti Nangalia,Charles E. Massie,E J Baxter,Francesca L. Nice,Gunes Gundem,David C. Wedge,Edward Avezov,Juan Li,Karoline Kollmann,David G. Kent,Athar Aziz,Anna L. Godfrey,Jonathon Hinton,Inigo Martincorena,P Van Loo,Amy V. Jones,Paola Guglielmelli,P. S. Tarpey,Heather P. Harding,J.D. Fitzpatrick,C.T. Goudie,Christina A. Ortmann,Stephen J. Loughran,Keiran Raine,David R. Jones,Adam Butler,Jon W. Teague,Sarah O’Meara,Stuart McLaren,M. Bianchi,Yvonne Silber,D. Dimitropoulou,David Bloxham,L. Mudie,Mark Maddison,Bruce W. S. Robinson,Clodagh Keohane,Cathy MacLean,Kate Hill,Kim Orchard,Sudhir Tauro,Ming-Qing Du,Mel Greaves,David G. Bowen,Brian J. P. Huntly,Claire N. Harrison,Nicholas C.P. Cross,David Ron,Alessandro M. Vannucchi,Elli Papaemmanuil,Peter J. Campbell,Anthony R. Green +51 more
TL;DR: Somatic mutations in the endoplasmic reticulum chaperone CALR were found in a majority of patients with myeloproliferative neoplasms with nonmutated JAK2, a finding consistent with its role as an initiating mutation in some patients.
Journal ArticleDOI
Deletion of chromosome 20q in myelodysplasia can occur in a multipotent precursor of both myeloid cells and B cells.
Nicholas White,Elisabeth P. Nacheva,Fotios A. Asimakopoulos,David Bloxham,Beverley Paul,Anthony R. Green +5 more
TL;DR: This represents the first report in which a chromosome abnormality associated with MDS has been immortalized in an EBV-transformed lymphoblastoid cell line and shows that patients with apparent myeloid restriction of a chromosome deletion may in fact have a disease arising in a multipotent cell with both myeloids and lymphoid potential.
Journal ArticleDOI
Guidelines on the use of multicolour flow cytometry in the diagnosis of haematological neoplasms
Ulrika Johansson,David Bloxham,Stephen Couzens,Jennifer Jesson,Ricardo Morilla,Wendy N. Erber,Marion G. Macey +6 more
TL;DR: This research aims to provide real-time information about what is happening in the operating theatre to improve the quality of care and reduce the likelihood of adverse events.
Journal ArticleDOI
Philadelphia-negative chronic myeloid leukaemia: detection by FISH of BCR-ABL fusion gene localized either to chromosome 9 or chromosome 22.
TL;DR: In one patient, analysis of metaphase spreads showed that the 3’region of the ABL gene was deleted from one chromosome 9 and inserted into chromosome 22, and in a second patient 5’BCR sequences were missing from one copy of chromosome22, and co‐localized with 3'ABL sequences on chromosome 9.
Journal ArticleDOI
Molecular detection of clonally rearranged cells in peripheral blood progenitor cell harvests from multiple myeloma patients.
J. M. Bird,David Bloxham,D. Samson,Robert Marcus,Nigel H. Russell,Stephen M. Kelsey,Adrian C. Newland,J. F. Apperley +7 more
TL;DR: Peripheral blood progenitor cells (PBPC) are increasingly used for autologous reconstitution following high‐dose chemotherapy in multiple myeloma but it is unclear whether these cells are less likely to be contaminated with malignant cells than bone marrow.